Cleo Diagnostics (ASX:COV) Cash And Cash Equivalents : A$10.11 Mil (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics Cash And Cash Equivalents?

Cleo Diagnostics's quarterly cash and cash equivalents declined from Dec. 2022 (A$0.80 Mil) to Jun. 2023 (A$0.24 Mil) but then increased from Jun. 2023 (A$0.24 Mil) to Dec. 2023 (A$10.11 Mil).

Cleo Diagnostics's annual cash and cash equivalents stayed the same from . 20 (A$0.00 Mil) to . 20 (A$0.00 Mil) but then increased from . 20 (A$0.00 Mil) to Jun. 2023 (A$0.24 Mil).

Cleo Diagnostics Cash And Cash Equivalents Historical Data

The historical data trend for Cleo Diagnostics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics Cash And Cash Equivalents Chart

Cleo Diagnostics Annual Data

Trend

Jun23

Cash And Cash Equivalents

0.24

Cleo Diagnostics Semi-Annual Data
	Dec22	Jun23	Dec23
Cash And Cash Equivalents	0.80	0.24	10.11

Cleo Diagnostics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Cleo Diagnostics (ASX:COV) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Cleo Diagnostics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Cleo Diagnostics (ASX:COV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000

Website

https://www.cleodx.com

Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The Company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics (ASX:COV) Headlines

No Headlines